Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
Details
Publication Year 2021-05-03, Volume 12, Issue #1, Page 2487
Journal Title
Nature Communications
Abstract
ARIEL2 (NCT01891344) is a single-arm, open-label phase 2 study of the PARP inhibitor (PARPi) rucaparib in relapsed high-grade ovarian carcinoma. In this post hoc exploratory biomarker analysis of pre- and post-platinum ARIEL2 samples, RAD51C and RAD51D mutations and high-level BRCA1 promoter methylation predict response to rucaparib, similar to BRCA1/BRCA2 mutations. BRCA1 methylation loss may be a major cross-resistance mechanism to platinum and PARPi. Genomic scars associated with homologous recombination deficiency are irreversible, persisting even as platinum resistance develops, and therefore are predictive of rucaparib response only in platinum-sensitive disease. The RAS, AKT, and cell cycle pathways may be additional modulators of PARPi sensitivity.
Publisher
NPG
WEHI Research Division(s)
Cancer Biology And Stem Cells
PubMed ID
33941784
Open Access at Publisher's Site
https://doi.org/10.1038/s41467-021-22582-6
Rights Notice
Refer to copyright notice on published article.


Creation Date: 2021-05-11 04:12:17
Last Modified: 2021-05-17 11:29:22
An error has occurred. This application may no longer respond until reloaded. Reload 🗙